Gemcitabine and cisplatine (GC) doublet
in the treatment of locally advanced or metastatic non small cell
lung cancer (NSCLC): Experience of the Department of Medical Oncology
2003 - Abstract n° 2733
M. Gamaz, K. Bouzid; Medical Oncology,
The aim of the study were to determine the efficacy and toxicity
of the GC combination in patients (pts) with NSCLC.
Patients and methods : Pts with
locally advanced or metastatic NSCLC received C 70 mg/m2 on day
1 and G 1250 mg/m2 on days 1 and 8 every 3 weeks.
Results : from January 1998 to
September 2002, 167 pts (151 male, 16 female) were treated in our
single institution. The median age of the pts was 57,3 years (range:
27-76). Histological subtypes were adenocarcinoma in 68 pts, squamous
celle carcinoma in 88 pts, and large cell carcinoma in 11 pts. Stage
IIIA, IIIB, and IV disease was reported in 21, 60 and 86 pts, respectively.
A total of 638 cycles was admistered, with a median of 6 cycles
(range, 3-9) per pt. Of the 146 evaluable pts, 2 (1,4%) had complete
response and 41(28,1%) had partial response, for an overall response
rate of 29,5%. Progressive disease was observed in 74 (50,7%) pts
and stable disease in 29 (20%) pts. The median time to progression
was 6 months (CI 2-10 months) and the median survival time was 7,8
months (CI 4,7-10,9 months). Grade 3-4 (CTC-NCI) hematological toxicities
were neutropenia in 1,8% thrombocytopenia in 1,2% and anemia in
9,4% of pts. No febrile neutropenia, no grade 3-4 non-hematological
toxicities and no death occured during this trial.
Conclusion : The results of our
single institution study confirm that GC is an effective and well-tolerated
regimen. Based on our experience, we consider the GC doublet a treatment
options for pts with NSCLC.
A phase II study of gemcitabine (G)
and cisplatin (C) combination in the treatment of recurrent cervical
squamous cell carcinoma (RCSCC)
2003 - Abstract n° 1900
K. Bouzid, H. Mahfouf; Department
of Medical Oncology, E.H.S Pierre & Marie Curie Center, Algiers,
Introduction : Gemcitabine, a
nucleoside analog, possesses activity in the treatment of RCSCC
(Proc ASCO 1996, abs #819; Proc ASCO 2000, abs #1549; Proc ASCO
2001, abs #824).
Objectives : Evaluate efficacy
and toxicity of G plus C in pretreated pts with RCSCC.
Methods : Since December 1998,
57 pts received 6 courses of G 1,250 mg/m2 d1 & 8 plus C 70 mg/m2
Eligibility criteria : histologically
verified cervical squamous cell carcinoma, PS£2, adequate bone marrow
reserve, good liver/kidney function, life expectancy exceeding 12
wks, and written informed consent.
Results : Fifty-seven pts enrolled
and 46 pts were evaluable for response.
Pt characteristics : median age
53 yrs (range 31-69), FIGO stage II bulky disease (21 pts), stage
III (25), stage IVA (11). Six pts relapsed after surgery, 38 pts
after radiation therapy (RT), and 13 pts after surgery plus RT.
Sites of recurrence : local (44
pts), bone (5), lymph nodes (4), lung (3), liver (1). A total of
254 cycles was administered. Overall response rate was 50%, with
a complete response in 7 pts (15%), a partial response in 16 (35%),
and stable disease in 3 (7%). Twenty pts (43%) progressed during
the study. Three pts with complete response relapsed after 4, 11,
and 12 mos, respectively. One-year and two-year survival were respectively
44% and 26%.
NCI-CTC grade 3 hematologic toxicity consisted
of : anemia (3%), thrombocytopenia (5%), neutropenia (1%);
no febrile neutropenia was reported.
Grade 3 nonhematologic toxicity :
Conclusion : The GC combination
is a promising regimen in the treatment of RCSCC.
Phase II trial with the gemcitabine
and cisplatin combination in the treatment of locally advanced and
metastatic gall bladder carcinoma
2003 - Abstract n° 1302
L. Abid, M. Oukkal, S. Berkane,
H. Mahfouf, J. Asselah, K. Bouzid; Department of Surgery, Noureddinne
El-Atassi Hospital, Algiers, Algeria; Department of Medical Oncology,
Pierre & Marie Curie Center, Algiers, Algeria
Introduction : Gall bladder carcinoma
is the leading cause of death among digestive tract cancers in Algerian
women, with an annual incidence of 8 per 100,000. It has both a
poor prognosis and low response to classic chemotherapeutic regimens.
Biliary tract cancer has the same embryologic origin as exocrine
pancreatic carcinoma. Because of the documented activity of gemcitabine
(G) and cisplatin (C) in the treatment of pancreatic cancer, this
combination may possess activity in gall bladder carcinoma.
Objectives : To determine the efficacy
and safety of G plus C in gall bladder carcinoma.
Methods : Between March 2000 to
Sept 2002, 36 pts received G 1,250 mg/m2 on d1,8 plus C 70 mg/m2
on d1, every 3 wks.
Inclusion criteria : no prior chemotherapy,
histologically proven carcinoma of the gall bladder, measurable
disease, PS £ 2, adequate renal/liver function, good bone marrow
reserve, life expectancy ³ 12 wks, written informed consent. Clinical
benefit response (CBR) was defined by analgesic consumption, PS,
and weight change. NCI-CTC grade 3/4 hematologic toxicity was evaluated
after 180 cycles.
Results : 36 pts enrolled. 23 pts
were evaluable for response; all pts were evaluable for toxicity
and CBR. Pt characteristics: M/F 3/33; median age 58 yrs (range
36-70). A total of 120 cycles was administered with a median of
3.3 (range 1-8). Overall response rate was 39%, with a CR in 4 pts
(17%), PR in 5 (22%), and SD in 4 (17%). A CBR was achieved in 19
pts (53%). Median survival was 5.7 months. Grade 3/4 hematologic
toxicity consisted of anemia (3% of cycles), neutropenia (4%), thrombopenia
(2%); no febrile neutropenia was reported. Grade 3/4 nonhematologic
toxicity: nephrotoxicity (2%).
Conclusions : Gemcitabine plus
cisplatin is an active and well-tolerated combination in the treatment
of gall bladder carcinoma. Moreover, the CBR data are particularly
interesting in relating to the improvement in the patients' quality